A Physiologically Based Pharmacokinetic Model to Predict Potential Drug-Drug Interactions of TPN171, a Novel Phosphodiesterase Type 5 Inhibitor.

TPN171 (a PDE5 inhibitor) is metabolised by CYP3A4; a PBPK model predicts the effect of CYP3A4 modulators.

Development and validation of a physiologically based pharmacokinetic (PBPK) model for TPN171, a novel PDE5 inhibitor metabolised by CYP3A4, to predict its drug-drug interactions. Validated against clinical data for itraconazole (strong inhibitor) and rifampicin (strong inducer), the model predicts a significant impact of strong and moderate inhibitors/inducers and a negligible effect of weak modulators. The authors derive a basis for dosing recommendations during co-administration.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Solid modelling work but on a niche drug (TPN171, not available in Europe) and without an associated CPIC recommendation. Mostly of methodological interest for anticipating CYP3A4 interactions. Retained this week given the limited pharmacogenetic volume; direct clinical impact is limited.

Analysis by Dr Thibaut Benquey